{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:50:50Z","timestamp":1793929850975,"version":"4.8.0"},"reference-count":16,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Idecabtagene vicleucel (ide-cel) is a chimeric antigen receptor (CAR) T-cell therapy approved for relapsed and refractory multiple myeloma (RRMM). Out-of-specification (OOS) CAR T cells not meeting criteria for commercial release are considered an investigational product; the expanded access protocol (EAP) allows release of OOS product for administration. The manufacturing analysis of capability, reliability, and timely delivery of ide-cel in the United States over &amp;gt;3 years since its approval included patients with RRMM who underwent leukapheresis for ide-cel treatment after \u22652 prior lines of therapy between 23 February 2021 and 1 November 2024. Additionally, the BB2121-EAP-001 study evaluated safety and efficacy of OOS ide-cel and included patients who had undergone leukapheresis for commercial ide-cel treatment not meeting commercial release specifications, most commonly due to high CD137 activation or low-infused dose. Primary end point was safety. Secondary end points were overall response rate (ORR) and complete response rate (CRR). At data cutoff (1 November 2024), the manufacturing success rate of ide-cel improved from 95.3% in 2021 to 96.8% in 2024. Turnaround time also improved from 31 days in 2021 to 24 days in 2024. In BB2121-EAP-001, 68 (72.3%) patients experienced \u22651 cytokine release syndrome event (mostly grade 1\/2) and 15 (16.0%) had neurological toxicities (2 grade 3, 13 grade 1\/2). ORR was 75.4% (95% confidence interval [CI], 63.1-85.2), and CRR was 35.4% (95% CI, 23.9-48.2). The manufacturing success of ide-cel is reliable and consistently high, and when OOS ide-cel products emerged, they demonstrated consistent clinical efficacy and safety. The BB2121-EAP-001 study was registered at www.clinicaltrials.gov as NCT04771078.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017186","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T20:52:44Z","timestamp":1774644764000},"page":"3769-3776","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Idecabtagene vicleucel manufacturing and clinical value of out-of-specification products in relapsed and refractory MM"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"first","affiliation":[{"name":"1Blood and Marrow Transplantation and Cell Therapy Division, Stanford University, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2326-2727","authenticated-orcid":false,"given":"Andrew J.","family":"Cowan","sequence":"additional","affiliation":[{"name":"3University of Washington School of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-7785","authenticated-orcid":false,"given":"Paula","family":"Rodr\u00edguez-Otero","sequence":"additional","affiliation":[{"name":"4Myeloma Unit, Cancer Center Cl\u00ednica Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6539-226X","authenticated-orcid":false,"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[{"name":"5Department I of Internal Medicine, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Mueller","sequence":"additional","affiliation":[{"name":"6Bristol Myers Squibb, Boudry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Broussard","sequence":"additional","affiliation":[{"name":"7Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Krengel","sequence":"additional","affiliation":[{"name":"7Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Li","sequence":"additional","affiliation":[{"name":"7Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Piault","sequence":"additional","affiliation":[{"name":"6Bristol Myers Squibb, Boudry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Corrao","sequence":"additional","affiliation":[{"name":"7Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Ho","sequence":"additional","affiliation":[{"name":"7Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-027X","authenticated-orcid":false,"given":"Krina","family":"Patel","sequence":"additional","affiliation":[{"name":"8Department of Lymphoma-Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"11","key":"2026060911321191000_bib1","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodr\u00edguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"2026060911321191000_bib2","unstructured":"Bristol Myers Squibb\n          . Bristol Myers Squibb Receives Approval for Abecma (idecabtagene vicleucel), the First CAR T Therapy Approved for the Treatment of Multiple Myeloma in Japan. Accessed 4 January 2024. https:\/\/news.bms.com\/news\/details\/2022\/Bristol-Myers-Squibb-Receives-Approval-for-Abecma-idecabtagene-vicleucel-the-First-CAR-T-Therapy-Approved-for-the-Treatment-of-Multiple-Myeloma-in-Japan\/default.aspx."},{"key":"2026060911321191000_bib3","article-title":"ABECMA (idecabtagene vicleucel). Summary of product characteristics","year":"2022","journal-title":"Celgene"},{"key":"2026060911321191000_bib4","article-title":"ABECMA (idecabtagene vicleucel). Package insert","year":"2021","journal-title":"Celgene"},{"issue":"8","key":"2026060911321191000_bib5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"2026060911321191000_bib6","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/j.clml.2024.01.014","article-title":"Optimizing the CAR T-cell therapy experience in multiple myeloma: clinical pearls from an expert roundtable","volume":"24","author":"Ailawadhi","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026060911321191000_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.19.00086","article-title":"Impact of increasing wait times on overall mortality of chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a discrete event simulation model","volume":"3","author":"Tully","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"issue":"11","key":"2026060911321191000_bib8","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.18609\/cgti.2018.105","article-title":"Management of \u2018out of specification\u2019 commercial autologous CAR-T cell products","volume":"4","author":"Bersenev","year":"2018","journal-title":"Cell Gene Ther Insights"},{"issue":"12","key":"2026060911321191000_bib9","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric antigen receptor T-cell therapies: barriers and solutions to access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"2026060911321191000_bib10","unstructured":"Bristol Myers Squibb\n          . Cell Therapy 360: Your Partner Throughout the CAR T Cell Therapy Treatment Journey. Accessed 5 January 2025. https:\/\/www.abecma.com\/resources\/cell-therapy-360."},{"key":"2026060911321191000_bib11","author":"Bristol Myers Squibb","year":"2025"},{"issue":"2","key":"2026060911321191000_bib12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2026060911321191000_bib13","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2026060911321191000_bib14","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1182\/blood-2024-194645","article-title":"Global manufacturing experience with idecabtagene vicleucel in patients with relapsed and refractory multiple myeloma","volume":"144","author":"Sidana","year":"2024","journal-title":"Blood"},{"key":"2026060911321191000_bib15","article-title":"CARVYKTI (ciltacabtagene autoleucel). Package insert","year":"2024","journal-title":"Janssen Biotech"},{"issue":"3","key":"2026060911321191000_bib16","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/bjh.19505","article-title":"French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed\/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry","volume":"205","author":"Ferment","year":"2024","journal-title":"Br J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/3769\/2523394\/blooda_adv-2025-017186-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/3769\/2523394\/blooda_adv-2025-017186-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:32:21Z","timestamp":1781019141000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/11\/3769\/567461\/Idecabtagene-vicleucel-manufacturing-and-clinical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017186","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,9]]},"published":{"date-parts":[[2026,5,27]]}}}